Bicara Therapeutics Inc. Common Stock

BCAXNASDAQHealthcare● Active

$20.10

+$0.10(+0.50%)

Market Cap$1.1B

P/E Ratio—

52W High$24.25

52W Low$8.48

Avg Volume557K

Open$20.55

Beta-0.53

Cash on Hand Financials Revenue

Bicara Therapeutics Inc. Common Stock (BCAX) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

BCAX · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$414.8M▼ -15.3% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$96.7M

cashAndCashEquivalents

Short-Term Investments

$318.1M

shortTermInvestments

YoY Change vs Prior Year

-15.3%

vs prior fiscal year

Latest Quarter

$539.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$414.8MCash on Hand

Total Debt$1.7MTotal Debt

Net Cash / Net Debt+$413.1MNet Cash Position

Cash vs Debt Ratio

Cash 100%Bicara Therapeutics Inc. Common Stock cash as % of market cap: 37.67%% · MCap $1BDebt 0%

Bicara Therapeutics Inc. Common Stock has a net cash position of $413.1M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$414.8M − $1.7M = +$413.1M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

BCAX annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

BCAX cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$414.8M-15.3%

Dec 31, 2024FY$489.7M+112.5%

Dec 31, 2023FY$230.4M+5442.1%

Dec 31, 2022FY$4.2M—

BCAX cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

BCAX vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Bicara Therapeutics Inc. Common StockYOU

BCAX

$414.8M$1B37.7%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Bicara Therapeutics Inc. Common Stock (BCAX) cash on hand as of December 31, 2025 is $414.8M, comprising $96.7M in cash and cash equivalents (CCE) plus $318.1M in short-term investments — reported as Bicara Therapeutics Inc. Common Stock cash and short-term investments on the balance sheet (10-K filing). Also referred to as Bicara Therapeutics Inc. Common Stock cash reserves or cash position.

Bicara Therapeutics Inc. Common Stock annual cash on hand history shows decreased -15.3% in 2025: decreased -15.3% in 2025. Bicara Therapeutics Inc. Common Stock cash reserves in 2025 reflect the company's capital allocation strategy.

Bicara Therapeutics Inc. Common Stock carries total debt of $1.7M against cash of $414.8M, resulting in a net cash position of +$413.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

BCAX cash on hand · 5 questions

As of December 31, 2025, Bicara Therapeutics Inc. Common Stock (BCAX) has $414,801,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $96,685,000 in cash and cash equivalents (CCE) plus $318,116,000 in short-term investments. Latest quarter (March 31, 2026): $539,753,000. Data sourced from the annual 10-K filing via FMP.

BCAX cash on handBCAX cash reservesBCAX cash 2025how much cash does BCAX have

▸ Source: FMP /balance-sheet-statement · US GAAP · Bicara Therapeutics Inc. Common Stock · Bicara Therapeutics Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025